Prognostic Significance of ESR1 Amplification and ESR1 PvuII, CYP2C192, UGT2B152 Polymorphisms in Breast Cancer Patients

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Aug 17

PMID 23951298

Citations 12

Authors

Aleksandra Markiewicz

Marzena Welnicka-Jaskiewicz

Jaroslaw Skokowski

Janusz Jaskiewicz

Jolanta Szade

Jacek Jassem

Anna J Zaczek

Affiliations

Soon will be listed here.

Abstract

Introduction: Amplification of the ESR1 gene, coding for estrogen receptor alpha, was shown to predict responsiveness to tamoxifen, however its prognostic impact in breast cancer patients has not been thoroughly investigated. Other factors that could contribute to responsiveness to tamoxifen treatment are polymorphisms in ESR1 gene and genes involved in tamoxifen metabolism. The aim of this study was to assess the prognostic role of ESR1 gene dosage in a consecutive group of breast cancer patients and to correlate this feature with clinico-pathological factors. Additionally, ESR1 PvuII, CYP2C19*2 and UGT2B15*2 polymorphisms were analyzed in the tamoxifen-treated subgroup of patients.

Materials And Methods: Primary tumor samples from 281 stage I-III consecutive breast cancer patients were analyzed for ESR1 gene dosage using real-time PCR with locked nucleic acids hydrolysis probes. In the tamoxifen-treated subgroup of patients, ESR1 PvuII, CYP2C19*2 and UGT2B15*2 polymorphism in leukocytes genomic DNA were analyzed. Results were correlated with clinico-pathological factors and with disease-free survival (DFS) and overall survival (OS).

Results: ESR1 amplification (with a cut-off level of 2.0) was found in 12% of the entire group of breast cancer patients, and in 18% of the ER-negative subgroup. This feature was associated with decreased DFS both in the entire group (P=0.007) and in the ER-negative subgroup (P=0.03), but not in the tamoxifen-treated patients. Patients with ESR1 PvuII wt/wt genotype and at least one UGT2B15 wt allele had a worse DFS (P=0.03) and showed a trend towards decreased Os (P=0.08) in comparison to patients with ESR1 PvuII wt/vt or vt/vt genotype and UGT2B15 *2/*2 genotype.

Conclusions: ESR1 amplification can occur in ER-negative tumors and may carry poor prognosis. In the tamoxifen-treated subgroup, poor prognosis was related to the combined presence of ESR1 PvuII wt/wt and UGT2B15wt/wt or wt/*2 genotype.

Citing Articles

Upregulation of miR-99b-5p Modulates ESR1 Expression as an Adaptive Mechanism to Circumvent Drug Response via Facilitating ER/HER2 Crosstalk.

Noyan S, Gur Dedeoglu B Balkan Med J. 2025; 42(2):150-156.

PMID: 40033677 PMC: 11881538. DOI: 10.4274/balkanmedj.galenos.2025.2024-12-47.

Role of the Mediator Complex and MicroRNAs in Breast Cancer Etiology.

Maldonado E, Morales-Pison S, Urbina F, Jara L, Solari A Genes (Basel). 2022; 13(2).

PMID: 35205279 PMC: 8871970. DOI: 10.3390/genes13020234.

ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer.

Karsono R, Haryono S, Karsono B, Harahap W, Pratiwi Y, Aryandono T BMC Cancer. 2021; 21(1):1348.

PMID: 34930150 PMC: 8686387. DOI: 10.1186/s12885-021-09083-x.

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective.

Hernando C, Ortega-Morillo B, Tapia M, Moragon S, Martinez M, Eroles P Int J Mol Sci. 2021; 22(15).

PMID: 34360578 PMC: 8345926. DOI: 10.3390/ijms22157812.

Currently Applied Molecular Assays for Identifying Mutations in Patients with Advanced Breast Cancer.

Lee N, Park M, Song W, Jeon K, Jeong S Int J Mol Sci. 2020; 21(22).

PMID: 33233830 PMC: 7699999. DOI: 10.3390/ijms21228807.

References

Musgrove E, Sutherland R . Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009; 9(9):631-43. DOI: 10.1038/nrc2713. View

de Morais S, Wilkinson G, Blaisdell J, Nakamura K, Meyer U, Goldstein J . The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994; 269(22):15419-22. View

Bocchinfuso W, Korach K . Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia. 2000; 2(4):323-34. DOI: 10.1023/a:1026339111278. View

Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J . qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 2007; 8(2):R19. PMC: 1852402. DOI: 10.1186/gb-2007-8-2-r19. View

Cai Q, Shu X, Jin F, Dai Q, Wen W, Cheng J . Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev. 2003; 12(9):853-9. View

Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger U . Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007; 25(33):5187-93. DOI: 10.1200/JCO.2007.12.2705. View

Ryan J, Canonico M, Carcaillon L, Carriere I, Scali J, Dartigues J . Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study. PLoS One. 2012; 7(3):e34112. PMC: 3311587. DOI: 10.1371/journal.pone.0034112. View

Yoshidome K, Shibata M, Couldrey C, Korach K, Green J . Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression. Cancer Res. 2001; 60(24):6901-10. View

Desta Z, Zhao X, Shin J, Flockhart D . Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002; 41(12):913-58. DOI: 10.2165/00003088-200241120-00002. View

10.

Tomita S, Zhang Z, Nakano M, Ibusuki M, Kawazoe T, Yamamoto Y . Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci. 2009; 100(6):1012-7. PMC: 11159263. DOI: 10.1111/j.1349-7006.2009.01145.x. View

11.

Nowell S, Ahn J, Rae J, Scheys J, Trovato A, Sweeney C . Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat. 2005; 91(3):249-58. DOI: 10.1007/s10549-004-7751-x. View

12.

Hill S, Fuqua S, Chamness G, Greene G, McGuire W . Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res. 1989; 49(1):145-8. View

13.

Abecasis G, Altshuler D, Auton A, Brooks L, Durbin R, Gibbs R . A map of human genome variation from population-scale sequencing. Nature. 2010; 467(7319):1061-73. PMC: 3042601. DOI: 10.1038/nature09534. View

14.

Levesque E, Beaulieu M, Green M, Tephly T, Belanger A, Hum D . Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics. 1997; 7(4):317-25. DOI: 10.1097/00008571-199708000-00007. View

15.

Vincent-Salomon A, Raynal V, Lucchesi C, Gruel N, Delattre O . ESR1 gene amplification in breast cancer: a common phenomenon?. Nat Genet. 2008; 40(7):809. DOI: 10.1038/ng0708-809a. View

16.

Nielsen K, Ejlertsen B, Muller S, Moller S, Rasmussen B, Balslev E . Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2010; 127(2):345-55. DOI: 10.1007/s10549-010-0984-y. View

17.

Holst F, Stahl P, Ruiz C, Hellwinkel O, Jehan Z, Wendland M . Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet. 2007; 39(5):655-60. DOI: 10.1038/ng2006. View

18.

Ruiter R, Bijl M, van Schaik R, Berns E, Hofman A, Coebergh J . CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics. 2010; 11(10):1367-75. DOI: 10.2217/pgs.10.112. View

19.

. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-717. DOI: 10.1016/S0140-6736(05)66544-0. View

20.

Okishiro M, Taguchi T, Kim S, Shimazu K, Tamaki Y, Noguchi S . Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer. 2009; 115(5):952-61. DOI: 10.1002/cncr.24111. View

Prognostic Significance of ESR1 Amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 Polymorphisms in Breast Cancer Patients

Prognostic Significance of ESR1 Amplification and ESR1 PvuII, CYP2C192, UGT2B152 Polymorphisms in Breast Cancer Patients